India Therapeutic Proteins Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Therapeutic Proteins Market was valued at USD 165.0 million in 2025 and is projected to reach USD 232.17 million by 2032, growing at a CAGR of approximately 5% during 2026–2032.
India Therapeutic Proteins Market Highlights
| Report Metric | Details |
| Report Name | India Therapeutic Proteins Market |
| Market Size 2025 | USD 165.0 million |
| Market Size 2032 | USD 232.17 million |
| Absolute Growth 2025–2032 | USD 67.17 million |
| CAGR 2026–2032 | 5% |
| Peak Annual Growth | 7.4% in 2026 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Protein Type, 2025 | Monoclonal Antibodies (44% share) |
| Leading Expression System, 2025 | CHO Cells (40% share) |
| Leading Application Area, 2025 | Oncology/Immunology (52% share) |
| Leading End User, 2025 | Biotech Firms (46% share) |
| Fastest-Growing Protein Type | Interferons (7.0% CAGR) |
| Fastest-Growing Expression System | Mammalian Cells (6.1% CAGR) |
| Fastest-Growing Application Area | Hematology (7.7% CAGR) |
| Fastest-Growing End User | Pharma R&D Units (6.3% CAGR) |
| Growing Sector | Hematology |
| Key End Users | Oncology/Immunology, Hematology, Inflammatory Diseases, Viral Infections |
India Therapeutic Proteins Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The following table presents the estimated annual growth rate for each year together with the principal factor influencing market performance.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 2.8 | The market exhibited steady growth, reflecting the ongoing expansion of the biotechnology sector in India. |
| 2023 | 5.6 | The growth rate accelerated, driven by increased production capabilities and demand from hospitals. |
| 2024 | 4.7 | Growth slowed as production costs rose, impacting the pricing strategies of suppliers. |
| 2025 | 2.7 | The market continued to grow, albeit at a slower pace, due to ongoing investments in biotech innovation. |
| 2026 | 7.4 | A surge in growth occurred, supported by the National Biotechnology Development Strategy enhancing production capabilities. |
| 2027 | 3.5 | Growth decelerated as the market adjusted to new production standards and regulatory requirements. |
| 2028 | 6.2 | The market experienced renewed growth, driven by advancements in therapeutic protein technologies and applications. |
| 2029 | 2.4 | Growth slowed again as the market faced challenges related to skilled workforce shortages in biotech. |
| 2030 | 6.9 | A rebound in growth was observed, fueled by increased investments in research and development for therapeutic proteins. |
| 2031 | 4.8 | The growth rate decreased, reflecting market adjustments to evolving regulatory landscapes and production costs. |
| 2032 | 3.9 | The market continued to grow, albeit at a moderated rate, as innovation efforts begin to yield results. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Therapeutic Proteins Market Synopsis
The India Therapeutic Proteins Market includes biologically active proteins designed to treat various diseases, primarily produced through recombinant DNA technology. These proteins play a crucial role in managing chronic conditions such as cancer and autoimmune disorders. The market is set to expand, driven by a robust biotechnology sector, with over 800 firms engaged in the production of therapeutic proteins. The National Biotechnology Development Strategy, initiated in 2021, aims to stimulate innovation and production capabilities, further boosting demand from domestic biotech firms and hospitals.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increasing investment in biotech startups focusing on therapeutic proteins | Driver | High | Biotech Firms |
| Growing patient population requiring chronic disease treatment | Driver | High | Hospitals |
| Rising demand for innovative therapies in oncology | Opportunity | High | Oncology/Immunology |
| Expansion of clinical labs adopting therapeutic proteins for diagnostics | Opportunity | Medium | Clinical Labs |
| Challenges in regulatory approvals for new therapeutic proteins | Restraint | High | Monoclonal Antibodies |
| Production costs affecting pricing strategies for manufacturers | Restraint | Medium | Monoclonal Antibodies |
| Limited access to advanced manufacturing technologies | Challenge | High | Biotech Firms |
| Competition from established international biopharmaceutical companies | Challenge | Medium | Monoclonal Antibodies |
Evaluation of Drivers in India Therapeutic Proteins Market (2026–2032)
The factors lifting demand, and the evidence behind each, are summarised below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increasing investments in biotech startups focusing on therapeutic proteins | Biotech Firms | Investments have surged by 30% in the last two years, enabling firms to expand their R&D capabilities. |
| Growing patient population requiring chronic disease treatment | Hospitals | India's population of approximately 1.4 billion creates a substantial demand for therapeutic proteins. |
| Rising demand for therapies in oncology | Oncology/Immunology | Monoclonal antibodies represent a large portion of the market, driving growth in this application area. |
| Expansion of clinical labs adopting therapeutic proteins for diagnostics | Clinical Labs | Clinical labs are increasingly using therapeutic proteins for diagnostics, enhancing their service offerings. |
| Support from government initiatives for biotech innovation | Monoclonal Antibodies | The National Biotechnology Development Strategy aims to boost innovation and production in the sector. |
Growth in the Therapeutic Proteins market in India is supported by increasing investments, a growing patient population, and heightened demand for therapies. With more than 800 biotech firms actively producing these proteins, hospitals and clinical labs are experiencing a notable rise in demand. The average annual growth rate of the Indian biotech sector stands at around 15%, highlighting strong interest in therapeutic proteins. Investments in biotech startups focusing on therapeutic proteins have surged by 30% over the past two years, enabling firms to improve their research capabilities. The expanding patient population of approximately 1.4 billion creates substantial demand for treatments targeting chronic diseases, particularly in oncology.
Evaluation of Restraints in India Therapeutic Proteins Market
The main factors holding the market back are set out below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Challenges in regulatory approvals for new therapeutic proteins | Monoclonal Antibodies | The Drug Regulatory Authority of India updated guidelines in 2022, complicating the approval process for manufacturers. |
| Production costs affecting pricing strategies for manufacturers | Monoclonal Antibodies | High production costs can limit profit margins and affect pricing strategies for therapeutic proteins, reducing competitiveness. |
| Limited access to advanced manufacturing technologies | Biotech Firms | Many firms struggle to access modern technologies, hindering their production capabilities and efficiency. |
| Competition from established international biopharmaceutical companies | Monoclonal Antibodies | Local firms face intense competition from global players, impacting their market share and pricing. |
| Market saturation affecting growth rates | Monoclonal Antibodies | As the market matures, growth rates are slowing due to increased competition and limited new entrants. |
India Therapeutic Proteins Market Challenges
The India Therapeutic Proteins Market encounters several practical challenges, with high production costs being a primary concern. Many suppliers face difficulties with the expenses linked to recombinant DNA technology, which can increase prices for buyers, especially hospitals, by as much as 20%. Buyers also experience delays in acquiring specialized therapeutic proteins due to limited supplier capabilities, which can extend treatment timelines for patients. A skills shortage in the biotech sector hampers growth, as the lack of trained professionals can diminish production efficiency, affecting suppliers' ability to meet demand. Outdated technology in some production facilities results in inefficiencies, causing delays that impact the timely delivery of products to clinics.
Trends in the India Therapeutic Proteins Market
Several trends are reshaping the India Therapeutic Proteins Market; the most important are set out below.
- Shift from Traditional to Advanced Therapeutic Proteins: Since 2021, the focus has shifted towards developing advanced therapeutic proteins, particularly monoclonal antibodies. This trend is reflected in the increasing number of biotech firms investing in R&D, with the market growing rapidly.
- Growing Adoption of Therapeutic Proteins in Clinical Labs: Clinical labs in Karnataka are increasingly adopting therapeutic proteins for diagnostics, reflecting a broader trend in the healthcare sector. This shift is supported by a 30% increase in investments in biotech startups over the last two years.
- Expansion of Oncology Applications for Therapeutic Proteins: The oncology application area has seen substantial growth since 2021, with a projected 52% market share by 2025. This expansion is driven by rising cancer cases and increased investments in research and development.
- Emergence of Biopharma Startups Focusing on Therapeutic Innovations: The last two years have seen a surge in biopharma startups dedicated to therapeutic innovations, particularly in oncology. This trend is supported by the National Biopharma Mission, which aims to develop new therapeutic proteins and vaccines.
Investment Opportunities in the India Therapeutic Proteins Market
Investors looking at the India Therapeutic Proteins Market should consider the following areas.
- Investment in Biotech Startups: With a projected growth of 30% in biotech investments, there is an opportunity for local partners to collaborate with startups focusing on therapeutic proteins in Karnataka.
- Expansion of Clinical Labs: The increasing adoption of therapeutic proteins in clinical labs presents opportunities for suppliers to provide advanced diagnostic solutions in urban areas, particularly in Maharashtra.
- Development of New Therapeutic Applications: The growing demand for innovative therapies in oncology creates opportunities for firms to invest in research and development of new therapeutic applications, particularly in Delhi.
- Partnerships with Hospitals: As hospitals expand their treatment options, there is an opportunity for suppliers to establish partnerships, particularly in the southern regions of India, to enhance therapeutic protein availability.
Government Initiatives in the India Therapeutic Proteins Market
The National Biotechnology Development Strategy 2021 aims to strengthen India's position in the global biotech market, focusing on therapeutic proteins and biopharmaceuticals. This strategy encourages investment in research and development, which is crucial for the growth of therapeutic proteins. Additionally, the Drug Regulatory Authority of India updated the guidelines for the approval of therapeutic proteins in 2022, streamlining the process for manufacturers and ensuring timely access to innovative treatments for patients. The implementation of these measures is expected to boost production efficiency and regulatory compliance among producers, ultimately benefiting buyers.
The Biopharma Mission, launched in 2020 with a budget of INR 1500 crore, supports the development of therapeutic proteins and vaccines. The Department of Biotechnology oversees this initiative, which funds research and development projects aimed at enhancing the therapeutic proteins landscape in India. Furthermore, the Biotechnology Industry Research Assistance Council (BIRAC) initiated the 'Innovative Biopharmaceuticals' program in 2021 to promote research in therapeutic proteins. This program provides financial assistance and support to biotech firms, enabling them to innovate and expand their product offerings.
Future Insight of the India Therapeutic Proteins Market
The India Therapeutic Proteins Market is set for transformation by 2032, driven by several pivotal factors. The National Biotechnology Development Strategy will stimulate innovation, while the Biopharma sector is projected to grow, with investments in biotech startups focusing on therapeutic proteins rising by 30% in the last two years. New initiatives from the Indian government aim to increase the share of biopharmaceuticals in the global market. Consequently, buyers will gain improved access to a wider array of therapeutic options, while suppliers will experience enhanced production capabilities and expanded market opportunities.
Market Segmentation Analysis
The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.
By Protein Type – Monoclonal Antibodies Dominated, Interferons Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, Monoclonal Antibodies took a 44% share of protein type in 2025, more than any other category. Monoclonal antibodies hold the largest share in the Indian therapeutic proteins market due to their extensive use in treating conditions like cancer and autoimmune disorders. Their established presence in various healthcare settings, such as oncology clinics, reinforces their dominant position. Over 2026–2032, Interferons are expected to post the fastest growth, at a CAGR of 7.0%. Interferons are rapidly gaining traction as they are increasingly utilised for antiviral therapies and cancer treatment, reflecting a shift in therapeutic approaches. This growth is supported by ongoing studies from the Indian Council of Medical Research, which aim to assess their effectiveness against infectious diseases. Suppliers should focus on enhancing the production of monoclonal antibodies and interferons to meet the rising demand in the therapeutic proteins market.
By Expression System – CHO Cells Dominated, Mammalian Cells Expected to Grow Fastest
With a 40% revenue share in 2025, CHO Cells was the largest expression system category. CHO cells dominate the market share as they are the primary system for producing therapeutic proteins, crucial for a variety of treatments. Their proven reliability and efficiency in production make them the preferred choice among manufacturers in India. Mammalian Cells are projected to grow fastest, at a CAGR of 6.1% during 2026–2032. Mammalian cells are experiencing rapid growth because they facilitate essential post-translational modifications, which are critical for the functionality of therapeutic proteins. This trend is likely to continue as the demand for more complex and effective proteins increases. Buyers should prioritise suppliers that utilise mammalian cells to ensure access to advanced therapeutic proteins with enhanced efficacy.
By Application Area – Oncology/Immunology Dominated, Hematology Expected to Grow Fastest
Oncology/Immunology held a 52% share of the India Therapeutic Proteins Market by application area in 2025. Oncology and immunology represent the largest application area for therapeutic proteins, driven by the high prevalence of cancer and autoimmune diseases in India. This focus has resulted in substantial investments and research directed towards these therapeutic areas. Hematology is set to record the highest CAGR in this split, 7.7% over 2026–2032. Hematology is the fastest-growing application area as therapeutic proteins become vital for treating blood-related conditions, reflecting a growing recognition of their importance. The increasing patient population requiring such treatments further fuels this growth. Suppliers should align their product offerings with the growing needs in hematology to capture emerging market opportunities.
By End User – Biotech Firms Dominated, Pharma R&D Units Expected to Grow Fastest
The largest end user category in 2025 was Biotech Firms, with a 46% share of total revenue. Biotech firms capture the largest market share as they are the main users of therapeutic proteins for drug development, leveraging advancements in biotechnology. Their active role in innovation ensures a steady demand for these proteins within the therapeutic landscape. The quickest growth will come from Pharma R&D Units, forecast to expand at a CAGR of 6.3% between 2026 and 2032. Pharma R&D units are rapidly expanding as they focus on the research and development of new therapeutic proteins, driven by the need for innovative treatments. This growth underscores the increasing collaboration between the biotech and pharmaceutical sectors. Suppliers must engage with pharma R&D units to remain competitive in the evolving therapeutic proteins market.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Therapeutic Proteins Market Outlook
- Market Size of India Therapeutic Proteins Market, 2025
- Forecast of India Therapeutic Proteins Market, 2032
- Historical Data and Forecast of India Therapeutic Proteins Revenues & Volume for the Period 2022 - 2032F
- India Therapeutic Proteins Market Trend Evolution
- India Therapeutic Proteins Market Drivers and Challenges
- India Therapeutic Proteins Price Trends
- India Therapeutic Proteins Porter's Five Forces
- India Therapeutic Proteins Industry Life Cycle
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Protein Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Monoclonal Antibodies for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Interferons for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Colony Stimulating Factors for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Fusion Proteins for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Expression System for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By CHO Cells for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By E. coli for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Mammalian Cells for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Recombinant Systems for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Application Area for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Oncology/Immunology for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Viral Infections for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Hematology for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Inflammatory Diseases for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Biotech Firms for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Clinical Labs for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutic Proteins Market Revenues & Volume By Pharma R&D Units for the Period 2022 - 2032F
- India Therapeutic Proteins Import Export Trade Statistics
- Market Opportunity Assessment By Protein Type
- Market Opportunity Assessment By Expression System
- Market Opportunity Assessment By Application Area
- Market Opportunity Assessment By End User
- India Therapeutic Proteins Top Companies Market Share
- India Therapeutic Proteins Competitive Benchmarking By Technical and Operational Parameters
- India Therapeutic Proteins Company Profiles
- India Therapeutic Proteins Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Protein Type
- Monoclonal Antibodies
- Interferons
- Colony Stimulating Factors
- Fusion Proteins
By Expression System
- CHO Cells
- E. coli
- Mammalian Cells
- Recombinant Systems
By Application Area
- Oncology/Immunology
- Viral Infections
- Hematology
- Inflammatory Diseases
By End User
- Biotech Firms
- Clinical Labs
- Hospitals
- Pharma R&D Units
